Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2018Website:
http://www.adicetbio.comNext earnings report:
19 March 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 79 min agoDividend
Analysts recommendations
Institutional Ownership
ACET Latest News
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
What type of business is Adicet Bio?
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
What sector is Adicet Bio in?
Adicet Bio is in the Healthcare sector
What industry is Adicet Bio in?
Adicet Bio is in the Biotechnology industry
What country is Adicet Bio from?
Adicet Bio is headquartered in United States
When did Adicet Bio go public?
Adicet Bio initial public offering (IPO) was on 26 January 2018
What is Adicet Bio website?
https://www.adicetbio.com
Is Adicet Bio in the S&P 500?
No, Adicet Bio is not included in the S&P 500 index
Is Adicet Bio in the NASDAQ 100?
No, Adicet Bio is not included in the NASDAQ 100 index
Is Adicet Bio in the Dow Jones?
No, Adicet Bio is not included in the Dow Jones index
When was Adicet Bio the previous earnings report?
No data
When does Adicet Bio earnings report?
The next expected earnings date for Adicet Bio is 19 March 2025